Lilly Asian Ventures backs Impact’s PARP research again, chipping in for $30M Series C led by Decheng Capital

Lilly Asian Ventures backs Impact’s PARP research again, chipping in for $30M Series C led by Decheng Capital

Submitted by admin on August 4, 2018 - 12:14pm
Source: 
Endpoints
News Tags: 
Chian
PARP inhibitors
Lilly Asian Ventures
Headline: 
Lilly Asian Ventures backs Impact’s PARP research again, chipping in for $30M Series C led by Decheng Capital
snippet: 

A Chinese biotech running after the “best-in-class” title in the PARP inhibitor field has gathered $30 million to fuel its still early-stage R&D work.

Do Not Allow Advertisers to Use My Personal information